![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The net proceeds will be used to advance two innovative, non-hormonal and non-antibiotic therapeutic programs for endometriosis and bacterial vaginosis.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: N/A Product Type: Undisclosed
Partner/Sponsor/Collaborator: Pivotal bioVenture Partners
Deal Size: $13.5 million Upfront Cash: Undisclosed
Deal Type: Financing January 03, 2024